Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Index funds offer low fees and broad diversification, making them a solid default choice for long-term investors.
26,735 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
SNDL investors are keenly watching Q4 2025 earnings for a read on revenue mix, cost discipline, and debt strategy. Th...
Gold climbs to new highs while Bitcoin retreats, setting the stage for a heated five-year debate on which asset shoul...
A Boston federal judge blocks jr.’s plan to cut childhood vaccine guidance, halting the changes pending a full hearin...
Cloudflare shares climbed about 8% on the day as investors bet NVIDIA’s AI acceleration will push more traffic throug...
The Senate delivers a bipartisan win with the ROAD to Housing Act, yet observers say the measure only scratches the s...
Bank of America upgrades Oracle to Buy, signaling potential upside as AI-driven cloud demand and a massive backlog cr...
A Ramsey Show caller with a $1.3M equity stake in a three‑unit property chooses an unconventional path: move aboard h...
Rocket Lab faces a pivotal Q1 print this evening as analysts weigh Neutron timing against a record backlog. Guidance ...
UWM Holdings said its controlling shareholder terminated a rules-based stock-sale program intended to boost float and...
An 18-year-old Barcelona star headlines a week of victory, celebrity moments, and a bold political gesture, reshaping...
Cisco posts record quarterly revenue as AI infrastructure orders rise, fueling renewed bets on CSCO. The article exam...